Show simple item record

dc.contributor.authorReimers, Arne
dc.contributor.authorBerg, Jon Andsnes
dc.contributor.authorBurns, Margrete Larsen
dc.contributor.authorBrodtkorb, Eylert
dc.contributor.authorJohannessen, Svein Ivar
dc.contributor.authorLandmark, Cecilie Johannessen
dc.date.accessioned2018-02-08T10:49:41Z
dc.date.accessioned2018-02-20T09:03:10Z
dc.date.available2018-02-08T10:49:41Z
dc.date.available2018-02-20T09:03:10Z
dc.date.issued2018
dc.identifier.citationReimers A, Berg JA, Burns M, Brodtkorb E, Johannessen Si, Landmark CJL. Reference ranges for antiepileptic drugs revisited: a practical approach to establish national guidelines. Drug Design, Development and Therapy. 2018;12:271-280en
dc.identifier.urihttps://hdl.handle.net/10642/5669
dc.description.abstractBackground and objective: Laboratories sometimes use different reference ranges for the same antiepileptic drug (AED), particularly for new and poorly investigated drugs. This may contribute to misunderstandings, concerns or inappropriate dose changes, which in turn may affect therapeutic effect, drug safety or treatment adherence. Therefore, the Norwegian Association of Clinical Pharmacology wished to update and harmonize the reference ranges for AEDs and establish national guidelines for Norway. Methods: A working group collected information on the reference ranges used by Norwegian laboratories for all commonly used AEDs. These reference ranges were compared to recent recommendations by the International League Against Epilepsy, current literature, applicable clinical studies, reference ranges used by leading Northern European epilepsy centers outside of Norway, and routine data derived from Norwegian laboratory databases. Results: Reference ranges varied between laboratories for four of 23 available AEDs (lamotrigine, valproate, eslicarbazepine and oxcarbazepine). For four AEDs (brivaracetam, perampanel, stiripentol and sulthiame), reference ranges had not previously been established. In total, 13 reference ranges were either harmonized, updated or newly established. No changes were applied to the remaining 10 AEDs. Conclusion: Updated and harmonized reference ranges are now available for 22 of the 23 AEDs available in Norway. The exception is vigabatrin (reference range not applicable). Revision of reference ranges is an important part of pharmacovigilance of AEDs and must be a continuous process based on current literature and clinical experience.en
dc.language.isoenen
dc.publisherDove pressen
dc.rightsThis work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.en
dc.rights.urihttps://creativecommons.org/licenses/by-nc/3.0/
dc.subjectAntiepileptic drugsen
dc.subjectSerum concentrationen
dc.subjectDrug monitoringen
dc.subjectVDP::Medisinske Fag: 700::Basale medisinske, odontologiske og veterinærmedisinske fag: 710::Farmakologi: 728en
dc.titleReference ranges for antiepileptic drugs revisited: a practical approach to establish national guidelinesen
dc.typeJournal articleen
dc.typePeer revieweden
dc.date.updated2018-02-08T10:49:41Z
dc.description.versionpublishedVersionen
dc.identifier.doihttp://doi.org/10.2147/DDDT.S154388
dc.identifier.cristinID1563154
dc.source.issn1177-8881
dc.relation.journalDrug Design, Development and Therapy


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.
Except where otherwise noted, this item's license is described as This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.